Our Global Head of Precision Medicine in Oncology discusses her day-to-day work at Novartis.

Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Researchers around the world are collaborating to provide solutions to immediate and future challenges.

Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Bioengineers, immunologists and clinicians collaborate to explore a new approach to fighting cancer.